Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04840901 · ClinicalTrials.gov registry record · Phase 1
A Study of Lebrikizumab (LY3650150) Administered by Two Different Devices in Healthy Participants
A Phase 1 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 242
- Enrollment target
NCT04840901 is a Phase 1 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 242 participants.
The verdict
NCT04840901, a Phase 1 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 242 participants
- Enrollment target
Study Summary
The main purpose of this study is to look at the amount of the study drug, lebrikizumab, that gets into the blood stream and how long it takes the body to get rid of lebrikizumab (LY3650150) when given using either a pre-filled autoinjector (AI) or a pre-filled syringe with needle safety device (PFS-NSD). The safety and tolerability of lebrikizumab will also be evaluated. The study will last up to 102 days.
Interventions
- DRUG Lebrikizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 242 participants |
| Start Date | 2021-06-02 |
| Est. Completion | 2022-02-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04840901
The ClinicalTrials.gov registry entry for NCT04840901 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 242 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Lebrikizumab is the first listed.
NCT04840901 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04840901 about?
NCT04840901 is a clinical study titled "A Study of Lebrikizumab (LY3650150) Administered by Two Different Devices in Healthy Participants". The main purpose of this study is to look at the amount of the study drug, lebrikizumab, that gets into the blood stream and how long it takes the body to get rid of lebrikizumab (LY3650150) when given using either a pre-filled autoinjector (AI) or a pre-filled syringe with needle safety device (PFS...
What is the current status of trial NCT04840901?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 242 participants. The study started on 2021-06-02. Estimated completion is 2022-02-11.
What interventions are being tested in trial NCT04840901?
The interventions under investigation include: Lebrikizumab (DRUG).
Who is sponsoring clinical trial NCT04840901?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.